Lexeo Therapeutics, Inc. (LXEO) stock
LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.85−0.38 (-11.61%)
Close on Nov 17, 2026Market cap $234.24MP/E –Yield –
Lexeo Therapeutics cash
Cash and short-term investments held at the end of each period.
Lexeo Therapeutics's cash was $234.20M at Jun 30, 2026. For fiscal 2025 it was $181.77M, up 41.5% from the year before. The highest annual figure on record is $181.77M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $181.77M | +41.5% |
| FY2024 | Dec 31, 2024 | $128.50M | +3.0% |
| FY2023 | Dec 31, 2023 | $124.72M | +54.8% |
| FY2022 | Dec 31, 2022 | $80.59M | -40.7% |
| FY2021 | Dec 31, 2021 | $135.86M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $234.20M | +72.0% |
| Q1 FY2026 | Mar 31, 2026 | $227.60M | +112.9% |
| Q4 FY2025 | Dec 31, 2025 | $181.77M | +41.5% |
| Q3 FY2025 | Sep 30, 2025 | $122.76M | -23.4% |
| Q2 FY2025 | Jun 30, 2025 | $136.14M | -23.6% |
| Q1 FY2025 | Mar 31, 2025 | $106.90M | -46.1% |
| Q4 FY2024 | Dec 31, 2024 | $128.50M | +3.0% |
| Q3 FY2024 | Sep 30, 2024 | $160.27M | +314.1% |
| Q2 FY2024 | Jun 30, 2024 | $178.23M | +265.3% |
| Q1 FY2024 | Mar 31, 2024 | $198.31M | +219.3% |
| Q4 FY2023 | Dec 31, 2023 | $124.72M | +54.8% |
| Q3 FY2023 | Sep 30, 2023 | $38.70M | -58.9% |
| Q2 FY2023 | Jun 30, 2023 | $48.79M | -64.1% |
| Q1 FY2023 | Mar 31, 2023 | $62.12M | – |
| Q4 FY2022 | Dec 31, 2022 | $80.59M | – |
| Q3 FY2022 | Sep 30, 2022 | $94.15M | – |
| Q4 FY2021 | Dec 31, 2021 | $135.86M | – |
See a number that looks wrong?